Suchergebnisse - "Asselah, Tarik"

PubPharm (10)

1

Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6) : an open-label, multicentre, phase 3b trial

enthalten in: The lancet. Gastroenterology & hepatology | 2019

von Asselah, T. | Lee, S. | Yao, B. | +13

CommentIn: Lancet Gastroenterol Hepatol. 2019 Jan;4(1):5-6. - PMID 30527582

2

Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older

enthalten in: PloS one | 2019

von Foster, G. | Asselah, T. | Kopecky-Bromberg, S. | +5

3

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2018

von Asselah, T. | Kowdley, K. | Zadeikis, N. | +19

4

Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

enthalten in: The New England journal of medicine | 2018

von Zeuzem, S. | Foster, G. | Wang, S. | +35

5

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection : 2 Phase 3 Randomized Trials

enthalten in: Gastroenterology | 2017

von Jacobson, I. | Lawitz, E. | Gane, E. | +27

6

Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET) : a single-arm, open-label, phase 3b trial

enthalten in: The lancet. Gastroenterology & hepatology | 2017

von Welzel, T. | Asselah, T. | Dumas, E. | +8

CommentIn: Lancet Gastroenterol Hepatol. 2017 Jul;2(7):465-466. - PMID 28416220

7

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

enthalten in: The New England journal of medicine | 2017

von Bourlière, M. | Gordon, S. | Flamm, S. | +127

8

Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I) : a multicentre, phase 3, randomised open-label trial

enthalten in: The lancet. Gastroenterology & hepatology | 2016

von Asselah, T. | Hézode, C. | Qaqish, R. | +11

CommentIn: Lancet Gastroenterol Hepatol. 2016 Sep;1(1):3-4. - PMID 28404109

9

Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II) : a multicentre, phase 3, partly randomised open-label trial

enthalten in: The lancet. Gastroenterology & hepatology | 2016

von Waked, I. | Shiha, G. | Qaqish, R. | +12

CommentIn: Lancet Gastroenterol Hepatol. 2016 Sep;1(1):3-4. - PMID 28404109

10

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I) : a randomised, open-label trial

enthalten in: Lancet (London, England) | 2015

von Hézode, C. | Asselah, T. | Reddy, K. | +11

CommentIn: Lancet. 2015 Jun 20;385(9986):2443-5. - PMID 25837828

1
[1]